Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasoni, Daniela, Fonarow, Gregg C., Adamo, Marianna, Anker, Stefan D., Butler, Javed, Coats, Andrew J.S., Filippatos, Gerasimos, Greene, Stephen J., McDonagh, Theresa A., Ponikowski, Piotr, Rosano, Giuseppe, Seferovic, Petar, Vaduganathan, Muthiah, Voors, Adriaan A., Metra, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303969/
https://www.ncbi.nlm.nih.gov/pubmed/34894038
http://dx.doi.org/10.1002/ejhf.2397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303969/
https://www.ncbi.nlm.nih.gov/pubmed/34894038
http://dx.doi.org/10.1002/ejhf.2397

Ejemplares similares